Financial Performance - In 2024, the company achieved operating revenue of 774 million yuan, a year-on-year increase of 12.04% [1] - The net profit attributable to shareholders reached 76.73 million yuan, a significant year-on-year growth of 134.66% [1] - The net profit after deducting non-recurring gains and losses was 51.21 million yuan, up 146.94% year-on-year [1] - Basic earnings per share were 0.18 yuan [1] Profitability Metrics - The gross profit margin for 2024 was 57.27%, an increase of 2.30 percentage points year-on-year [3] - The net profit margin improved to 9.90%, up 5.17 percentage points year-on-year [3] - The weighted average return on net assets was 4.68%, an increase of 2.65 percentage points year-on-year [3] Expense and Cash Flow Analysis - Total period expenses for 2024 amounted to 357 million yuan, a year-on-year increase of 7.03% [3] - Selling expenses were 251 million yuan, up 18.88% year-on-year due to increased academic promotion activities [3] - Research and development expenses decreased by 24.31% to 59.13 million yuan [3] - Net cash flow from operating activities was 162 million yuan, down 26.25% year-on-year [3] - Net cash outflow from investing activities was 107 million yuan, primarily for production base construction and smart transformation [3] Business Segment Performance - Revenue from the pharmaceutical industry was 651 million yuan, a year-on-year increase of 15.39%, accounting for 84.02% of total revenue [3] - Revenue from ear, nose, and throat medications was 265 million yuan, up 28.26% year-on-year [3] - Revenue from digestive system medications reached 178 million yuan, a year-on-year increase of 11.46% [3] - Revenue from psychiatric and neurological medications was 145 million yuan, up 14.06% year-on-year [3] New Business Developments - The company received approval for the special medical food project TY005, with production lines gradually releasing capacity [4] - E-commerce sales exceeded 13 million yuan [4] - The company is advancing four tumor-related Class 1 new drug pipelines, with the HSN003 project entering the IND application preparation stage [4] - A cash dividend of 0.50 yuan per 10 shares (including tax) is proposed for 2024 [4]

Group 1 - The core point of the announcement is that Chongqing Huason Pharmaceutical Co., Ltd. has received the Supplementary Application Approval Notice for Orlistat Capsules from the National Medical Products Administration, indicating a change in the marketing authorization holder [1][2] - Orlistat Capsules are currently the only approved oral treatment for obesity or overweight patients (BMI ≥ 24) in China, primarily working by reducing fat absorption from food [2][3] - The company has transitioned to self-branding "Quchang" for the sales operation of Orlistat Capsules after reaching an agreement with its partner to change the marketing authorization back to the partner while still allowing the company to produce the product [2][3] Group 2 - The company has also received re-registration approval notices for eight other drugs, ensuring their normal production and sales, which include Cang'erzi Nasal Inhalation Capsules and Spirulina Capsules among others [6][12] - Cang'erzi Nasal Inhalation Capsules are recognized as a classic medication for nasal diseases and are included in the national medical insurance list, indicating a strong market position [9] - Spirulina Capsules have shown significant effects in enhancing immunity and regulating blood lipids, supported by multiple clinical studies, which may enhance the company's product portfolio and market competitiveness [10][11]